• Products
  • Methods
  • RNAi Effects
  • FAQ
  • Order
  • Terms & Conditions
  • Privacy Policy
  • Company
  • Contact
AteloGene®

RNAi Effects



Local administration

Suppression of gene expression of subcutaneous tumor in mice

Local administration

When luciferase siRNA (Luc siRNA) was administered using "AteloGene®" against luciferase-expressing tumor cells that were subcutaneously grafted, the luciferase expression was more inhibited compared with the result observed after the administration of Luc siRNA alone.




Systemic administration

Suppression of gene expression of generalized metastasized tumors in mice

Systemic administration

When luciferase siRNA (Luc siRNA) was administered using "AteloGene®" against luciferase-expressing generalized metastasized tumor cells, the luciferase expression was more inhibited compared with the result observed after the administration of Luc siRNA alone.




References


Systemic Use

  1. Kawakami E, et al. Atelocollagen-mediated systemic administration of myostatin-targeting siRNA improves muscular atrophy in caveolin-3-deficient mice. (2011) Dev Growth Differ. 53(1):48-54.
  2. Zeng Y, et al. The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein. (2011) J Biol Chem. Feb 25. [Epub ahead of print]
  3. Adachi T, et al. Delivery of small interfering RNA with a synthetic collagen poly(Pro-Hyp-Gly) for gene silencing in vitro and in vivo. (2010) Dev Growth Differ. 52(8):693-699.
  4. Azuma K, et al. Anti-tumor effect of small interfering RNA targeting the androgen receptor in human androgen-independent prostate cancer cells. (2010) Biochem Biophys Res Commun. 391(1):1075-1079.
  5. Cheng L, et al. Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency. (2010) Oncogene. 29(42):5700-5711.
  6. Takeshita F, et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. (2010) Mol Ther. 18(1):181-187.
  7. Mu P, et al. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. (2009) Int J Cancer. 125(12):2978-2990.
  8. T. Ishimoto, et al. Downregulation of Monocyte Chemoattractant Protein-1 Involving Short Interfering RNA Attenuates Hapten-induced Contact Hypersensitivity. (2008) Mol Ther. 16(2):387-395
  9. N. Kinouchi, et al. Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass. (2008) Gene Ther. 15(15):1126-1130.
  10. F. Takeshita, et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. (2005) Proc. Nat. Acad. Sci. USA. 102(34):12177-12182.

Local Use

  1. Lorente M, et al. Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action. (2011) Cell Death Differ. Jan 14. [Epub ahead of print]
  2. Takei Y, et al. The Metastasis-Associated microRNA miR-516a-3p Is a Novel Therapeutic Target for Inhibiting Peritoneal Dissemination of Human Scirrhous Gastric Cancer. (2011) Cancer Res. 71(4):1442-1453.
  3. Liu CJ, et al. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. (2010) Cancer Res. 70(4):1635-1644.
  4. Marsaud V, et al. Cyclin K and cyclin D1b are oncogenic in myeloma cells. (2010) Mol Cancer. 9:103.
  5. Satow R, et al. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. (2010) Clin Cancer Res. 16(9):2518-2528.
  6. Shitashige M, et al. Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. (2010) Cancer Res. 70(12):5024-5033.
  7. Yamada A, et al. Cathepsin L inhibition prevents murine autoimmune diabetes via suppression of CD8(+) T cell activity.(2010) PLoS One. 5(9):e12894.
  8. Nagata Y, et al. Induction of apoptosis in the synovium of mice with autoantibody-mediated arthritis by the intraarticular injection of double-stranded MicroRNA-15a. (2009) Arthritis Rheum. 60(9):2677-2283.
  9. Shimada K, et al. A novel human AlkB homologue, ALKBH8, contributes to human bladder cancer progression. (2009) Cancer Res. 69(7):3157-3164
  10. Yamaguchi U, et al. Functional genome screen for therapeutic targets of osteosarcoma. (2009) Cancer Sci. 100(12):2268-2274.
  11. Bernard-Pierrot I, et al. Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. (2008) Cancer Res. 68(17):7165-7175.
  12. Iwaki K, et al. A small interfering RNA targeting proteinase-activated receptor-2 is effective in suppression of tumor growth in a Panc1 xenograft model. (2008) Int J Cancer. 122(3):658-663.
  13. Matoba T, et al. An siRNA against JC virus (JCV) agnoprotein inhibits JCV infection in JCV-producing cells inoculated in nude mice. (2008). Neuropathology 28(3):286-294.
  14. Migita T, et al. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. (2008) Cancer Res. 68(20):8547-8554.
  15. Yamato K, et al. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. (2008) Cancer Gene Ther. 15(3):140-153.
  16. Kokuryo T, et al. Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma. (2007) Cancer Res. 67(20):9637-9642.
  17. Yamashita M, et al. Involvement of aminopeptidase N in enhanced chemosensitivity to paclitaxel in ovarian carcinoma in vitro and in vivo. (2007) Int J Cancer. 120(10):2243-2250.
  18. Takei Y, et al. Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. (2006) Cancer. 107(4):864-873.